In most cases, Abbott is one of three or four competitors that dominate the market, including nutrition, cardiac rhythm management devices, surgical heart valves, continuous glucose monitors, coronary ...

Neuromodulation delivered an above-market performance, driven by Pain Stim growth, including strong U.S. growth propelled by the continued launch of the Inceptiv spinal cord stimulator.

We anticipate Livanova can bring leverage down to the target range by 2027, which would put the firm's debt at levels typical of medtech firms. Interest coverage remains well within covenants, though, ...

In Pain Stim we grew 12%, including 17% in the U.S., on the strength of our Inceptiv closed loop spinal cord stimulator ... on the integration work with the Abbott-based sensor.

The American Society of Pain and Neuroscience (ASPN) has just issued UPDATED guidelines for physicians using neuromodulation ...

Scientists have developed an approach that combines rehabilitation robotics with spinal cord stimulation to restore movement in people with spinal cord injuries. The technology enhances rehabilitation ...